(Press-News.org) The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this drug combination offers an added benefit over the appropriate comparator therapy.
According to the findings, an added benefit is not proven: For patients with moderate COPD severity and patients with fewer than two acute flare-ups (exacerbations) per year, evaluable data were only available on the outcomes "dyspnoea" and "health-related quality of life". However, these data showed no differences in comparison with tiotropium. For higher severity grades with more exacerbations, the drug manufacturer presented no evaluable analyses at all.
G-BA specified tiotropium as appropriate comparator therapy
In COPD, the lungs are permanently damaged, and the airways (bronchi) are continuously narrowed. This makes breathing more difficult. The symptoms can be relieved by drugs called bronchodilators, which widen the airways. Long-acting bronchodilators like umeclidinium and vilanterol are used on a long-term basis (with a dry powder inhaler) to relieve symptoms like dyspnoea in various ways.
The Federal Joint Committee (G-BA) distinguished between two constellations with regard to the appropriate comparator therapy: In adult patients with COPD severity grade II (moderate severity) and grades III/IV with fewer than two exacerbations per year, long-acting beta-2 sympathomimetics (formoterol, salmeterol) and/or long-acting anticholinergics (tiotropium) are to be used. In higher COPD severity grades (grade III or higher) with more than one exacerbation per year, inhaled corticosteroids (ICS) are to be used in addition.
Data only for patients with few exacerbations
The manufacturer only specified a comparator therapy (tiotropium) for the treatment of patients with moderate severity and patients with few exacerbations, and only claimed an added benefit for its fixed combination in comparison with this comparator therapy.
The manufacturer used three randomized controlled trials for the direct comparison of umeclidinium/vilanterol with tiotropium (DB2113360, DB2113374 and ZEP117115). In the studies, concomitant treatment with ICS was also allowed for moderate severity grades. However, this does not concur with the appropriate comparator therapy specified by the G-BA. Hence, only the data of approximately half of the study participants could be used for the assessment of the added benefit.
The analyses on the basis of the total population presented by the company were inadequate. IQWiG therefore used the analyses for the patients without concomitant ICS treatment as an approximation for patients with moderate COPD severity grades and patients with fewer than two exacerbations per year.
Lack of analyses for most outcomes
In moderate severity grades and patients with few exacerbations, the dossier contained no evaluable analyses on the outcome "mortality", most COPD symptoms, the frequency of moderate and severe exacerbations and side effects. There were evaluable results with regard to the symptom "dyspnoea" and health-related quality of life, but these showed no statistically significant differences between the treatment groups.
Since evaluable results on outcomes of mortality and morbidity and of all side effects are lacking, greater harm from umeclidinium/vilanterol cannot be excluded either. Hence no conclusive balancing can be conducted on the added benefit. An added benefit of the fixed combination of umeclidinium/vilanterol versus the appropriate comparator therapy is therefore not proven for patients with moderate COPD severity grades and patients with fewer than two exacerbations per year.
No analyses for higher severity grades
The manufacturer specified no comparator therapy for the second constellation in higher severity grades with more exacerbations and also claimed no added benefit: From the company's point of view, not enough patients with COPD grades III/IV with more than one exacerbation per year were included in the three studies cited.
In contrast to patients with few exacerbations, data extraction as an approximation for patients with higher severity grades and more exacerbations was not possible using the manufacturer's analyses. Since evaluable analyses are lacking, an added benefit of umeclidinium/vilanterol is also not proven for these patients.
G-BA decides on the extent of added benefit
The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G BA then decides on the extent of the added benefit, thus completing the early benefit assessment.
INFORMATION:
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website http://www.gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on umeclidinium/vilanterol.
The G-BA website contains both general English-language information on benefit assessment pursuant to §35a Social Code Book (SGB) V and specific German-language information on the assessment of umeclidinium/vilanterol.
More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on http://www.informedhealthonline.org). If you would like to be informed when these documents are available, please send an e-mail to info@iqwig.de.
Scientists at Nanyang Technological University (NTU Singapore) have discovered a new molecule which can join together chains of amino acids – the building blocks of protein.
Only three other known molecules have been discovered to be able to perform this function, which is an important process in the development of new drugs. A key difference is that the new molecule is able to do the same process 10,000 times faster than the other three and "cleanly" without leaving any residue behind.
This new molecule, which is a type of catalyst or enzyme, was derived from ...
Researchers at VTT Technical Research Centre of Finland, the University of Turku and the University of Oslo have discovered a previously unknown molecular-level mechanism that may partly explain the increased growth of cancer cells. The study, published in the British Journal of Cancer, showed that high levels of miRNA-378a-5p molecule cause cell division anomalies. This renders the number of chromosomes in cancer cells abnormal, which is known to promote growth and the spread of cancer. In addition, the researchers discovered that elevated miRNA378a-5p levels in breast ...
Laser physicists have built a tractor beam that can repel and attract objects, using a hollow laser beam that is bright around the edges and dark in its centre.
It is the first long-distance optical tractor beam and moved particles one fifth of a millimetre in diameter a distance of up to 20 centimetres, around 100 times further than previous experiments.
"Demonstration of a large scale laser beam like this is a kind of holy grail for laser physicists," said Professor Wieslaw Krolikowski, from the Research School of Physics and Engineering at The Australian National ...
What does a 1980s experimental aircraft have to do with state-of-the art quantum technology? Lots, as shown by new research from the Quantum Control Laboratory at the University of Sydney, and published in Nature Physics today.
Over several years a team of scientists has taken inspiration from aerospace research and development programs to make unusually shaped experimental aircraft fly.
"It always amazed me that the X-29, an American airplane that was designed like a dart being thrown backwards, was able to fly. Achieving this, in 1984, came through major advances ...
A pilot study testing a new type of drug in patients with chronic diarrhoea has shown promising effects on reducing their symptoms.
Bile acid diarrhoea (BAD) is a common cause of chronic diarrhoea that is estimated to affect one in 100 adults in western countries, but is often mistaken for irritable bowel syndrome (IBS) by doctors. Many patients are not diagnosed correctly and undergo repeated unnecessary tests.
The study at Imperial College London found that the drug obeticholic acid (OCA) could provide relief for patients with BAD. OCA is the first in a new class ...
Researchers at NYU Langone Medical Center conclude new drug in development may offer first alternative to standard chemotherapy for T-Cell Acute Lymphoblastic Leukemia.
Researchers at NYU Langone Medical Center and elsewhere say that blocking the action of an enzyme "switch" needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia.
An estimated quarter of the 500 U.S. adolescents and young adults diagnosed each year with this aggressive disease fail to respond to standard chemotherapy drugs that target cancer ...
Washington, D.C.— Hydrogen—the most abundant element in the cosmos—responds to extremes of pressure and temperature differently. Under ambient conditions hydrogen is a gaseous two-atom molecule. As confinement pressure increases, the molecules adopt different states of matter—like when water ice melts to liquid and then heats to steam. Thus far, at extreme pressures hydrogen has four known solid phases. Now scientists, including Carnegie's Alexander Goncharov, have combined hydrogen with its heavier sibling deuterium—which has an added neutron ...
This issue of Health Affairs was supported by CVS Health.
Do specialty drugs offer value that offsets their high costs?
James D. Chambers of Tufts Medical Center and coauthors conducted a cost-value review of specialty versus traditional drugs by analyzing incremental health gains associated with each. This first-of-its-kind analysis is timely because the majority of drugs now approved by the Food and Drug Administration are specialty drugs produced using advanced biotechnology and requiring special administration, monitoring, and handling—all of which result ...
Philadelphia, PA (October 20, 2014)–Promising new research in the area of hepatitis C (HCV) therapy that suggests more patients, including those with cirrhosis, will be cured from this common cause of potentially fatal viral liver disease; as well as a number of abstracts that advance understanding of the safety and effectiveness of fecal microbiota transplantation for Clostridium difficile, are among the highlights of the American College of Gastroenterology's (ACG) 79th Annual Scientific Meeting , which will be held this week in Philadelphia. More than 4,000 ...
DURHAM, N.C. – Scientists have developed new geochemical tracers that can identify hydraulic fracturing flowback fluids that have been spilled or released into the environment.
The tracers, which were created by a team of U.S. and French researchers, have been field-tested at a spill site in West Virginia and downstream from an oil and gas brine wastewater treatment plant in Pennsylvania.
"This gives us new forensic tools to detect if 'frac fluids' are escaping into our water supply and what risks, if any, they might pose," said Duke University geochemist Avner ...
